Argos Therapeutics (NASDAQ:ARGS) recently completed its IPO, raising $45 million in an offering at $8/share. This is far below the estimated range of $13-15 for which the company had initially hoped. The stock opened for trading on 02/07/14 at $8.90, and quickly dropped to the offering price of $8/share, with 19,048,958 shares outstanding, for a total market capitalization of $152m.
This company initially filed for an IPO in early 2012, then subsequently withdrew its application, citing market conditions. It would appear that the market was not any kinder to them this time around. Here, I detail my investment thesis on ARGS. As positive as I am on the technology, I would recommend avoiding this stock, as the cash...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|